Mak Capital One Lowers stake in Chemours Co (CC)

Chemours Co (CC) : Mak Capital One reduced its stake in Chemours Co by 9.14% during the most recent quarter end. The investment management company now holds a total of 2,786,841 shares of Chemours Co which is valued at $27.3 Million after selling 280,391 shares in Chemours Co , the firm said in a disclosure report filed with the SEC on May 13, 2016.Chemours Co makes up approximately 22.69% of Mak Capital One’s portfolio.

Other Hedge Funds, Including , Ancora Advisors reduced its stake in CC by selling 25,120 shares or 65.59% in the most recent quarter. The Hedge Fund company now holds 13,180 shares of CC which is valued at $129,296. Chemours Co makes up approx 0.02% of Ancora Advisors’s portfolio.Credit Agricole S A reduced its stake in CC by selling 163,940 shares or 99.2% in the most recent quarter. The Hedge Fund company now holds 1,326 shares of CC which is valued at $13,008.Smithfield Trust Co reduced its stake in CC by selling 76 shares or 6.44% in the most recent quarter. The Hedge Fund company now holds 1,105 shares of CC which is valued at $11,337. Bluecrest Capital Management Ltd added CC to its portfolio by purchasing 115,812 company shares during the most recent quarter which is valued at $1.2 Million. Chemours Co makes up approx 0.10% of Bluecrest Capital Management Ltd’s portfolio.Hall Laurie J Trustee reduced its stake in CC by selling 87 shares or 4.89% in the most recent quarter. The Hedge Fund company now holds 1,691 shares of CC which is valued at $15,422. Chemours Co makes up approx 0.01% of Hall Laurie J Trustee’s portfolio.

Chemours Co opened for trading at $9.31 and hit $9.67 on the upside on Wednesday, eventually ending the session at $9.58, with a gain of 3.79% or 0.35 points. The heightened volatility saw the trading volume jump to 37,66,846 shares. Company has a market cap of $1,738 M.

On the company’s financial health, Chemours Co reported $0.06 EPS for the quarter, based on the information available during the earnings call on May 2, 2016. Analyst had a consensus estimate of $0.06. The company had revenue of $1297.00 million for the quarter, compared to analysts expectations of $1267.06 million. The company’s revenue was down -4.8 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.33 EPS.

Many Wall Street Analysts have commented on Chemours Co. Company shares were Reiterated by Barclays on May 9, 2016 to “Overweight”, Firm has raised the Price Target to $ 15 from a previous price target of $14 .Chemours Co was Upgraded by Goldman to ” Buy” on Mar 14, 2016. Chemours Co was Downgraded by Jefferies to ” Hold” on Feb 16, 2016.

The Chemours Company (Chemours) is a provider of performance chemicals. The Company delivers solutions with a range of industrial and specialty chemical products for markets including plastics and coatings refrigeration and air conditioning general industrial and mining and oil refining. The Company operates through three segments: Titanium Technologies Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2) under the brands including Ti-Pure and Vantage. Its Fluoroproducts segment is a provider of fluoroproducts under the brands including Suva ISCEON Freon Opteon Teflon Tefzel Viton Krytox Formacel Dymel FM 200 Nafion and Capstone. Its Chemical Solutions segment is a provider of industrial and specialty performance chemicals under the brands including Virkon and Oxone. The Company’s products include titanium dioxide refrigerants industrial fluoropolymer resins sodium cyanide sulfuric acid and aniline.

Leave a Reply

Chemours Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Chemours Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.